{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:45Z","timestamp":1792839765719,"version":"4.5.0"},"reference-count":91,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic infection with hepatitis delta virus (HDV) leads to rapid progression of liver disease, cirrhosis and complications such as end\u2010stage liver disease and hepatocellular carcinoma. In recent years, understanding of the HDV life cycle has increased significantly; however, much remains unknown about the pathogenesis, host\u2010virus interactions and the role of the immune system in HDV persistence and control. Challenges remain in the diagnosis of HDV, not only because of the lack of standardised assays, but also because of limited access and availability in resource\u2010limited countries. The improved knowledge of the HDV life cycle has led to the development and approval of the first HDV\u2010direct antiviral, Bulevirtide (BLV). Treatment with BLV shows high rates of viral suppression in clinical trials and real\u2010world studies. Questions remain about the duration of treatment with BLV and the potential benefits of combination therapy with pegylated interferon alpha (PegIFN\u03b1). First data from the Phase III study in which BLV was stopped after 3\u2009years of treatment have recently been presented at congresses. Results from the Phase II study evaluating the combination of BLV and PegIFN\u03b1, as well as real\u2010world experiences, have been published. Despite recent advances in antiviral treatment, strategies to achieve HBsAg loss, which most closely resembles HDV cure, are not available and antiviral treatment for patients with advanced liver disease is limited. The third international Delta Cure meeting, held in Milan in October 2024, aimed to share the latest findings, and this review highlights key takeaways from the lectures and research on HDV.<\/jats:p>","DOI":"10.1111\/liv.70189","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T12:38:02Z","timestamp":1750423082000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4669","authenticated-orcid":false,"given":"Elisabetta","family":"Degasperi","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"D\u2010SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917)  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-2640","authenticated-orcid":false,"given":"Lisa","family":"Sandmann","sequence":"additional","affiliation":[{"name":"D\u2010SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917)  Hannover Germany"},{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Hannover Medical School  Hannover Germany"},{"name":"Excellence Cluster RESIST, Excellence Initiative Hannover Medical School  Hannover Germany"},{"name":"German Center for Infection Research (DZIF)  Braunschweig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-0480","authenticated-orcid":false,"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"D\u2010SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917)  Hannover Germany"},{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Hannover Medical School  Hannover Germany"},{"name":"Excellence Cluster RESIST, Excellence Initiative Hannover Medical School  Hannover Germany"},{"name":"German Center for Infection Research (DZIF)  Braunschweig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"D\u2010SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917)  Hannover Germany"},{"name":"Department of Pathophysiology and Transplantation, CRC \u201cA. M. and A. Migliavacca\u201d Center for Liver Disease University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Delta Cure 2024 Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_2_15_2_1","volume-title":"Guidelines for the Prevention, Diagnosis, Care and Treatment for People With Chronic Hepatitis B Infection","author":"World Health Organization","year":"2024"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.001"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15776"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.043"},{"key":"e_1_2_15_6_1","unstructured":"C.Valente R.Carvalho R.Lino et\u00a0al. \u201cHepatitis Delta Infection in Individuals Living With HIV \u2013 Multicentric Portuguese Study \u201dDelta Cure 3rd International Meeting Poster #17 https:\/\/www.deltacure2024.com\/download\/poster\/P17.pdf."},{"key":"e_1_2_15_7_1","unstructured":"G.Jargalsaikhan H.Kamal S.Enkhtaivan et\u00a0al. \u201cThe Prevalence and Characteristics of Hepatitis B\/D in 48 522 HBsAg Tested Individuals in Mongolia \u201dDelta Cure 3rd International Meeting Poster #8 https:\/\/www.deltacure2024.com\/download\/poster\/P8.pdf."},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14243"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30350-4"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03857.x"},{"key":"e_1_2_15_11_1","first-page":"S57A","article-title":"Factors Associated With Severe Fibrosis in Patients Presenting With Hepatitis Delta to a Referral Center in Pakistan","volume":"64","author":"Channa S. H.","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001238"},{"key":"e_1_2_15_13_1","unstructured":"C.Eber R.Fouill\u00e9 E.Gerges et\u00a0al. \u201cDeciphering the Cellular Response to IFN Treatment in HDV\u2010Infected Cells \u201dDelta Cure 3rd International Meeting Poster #50 https:\/\/www.deltacure2024.com\/download\/poster\/P50.pdf."},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314713"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.023"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100673"},{"key":"e_1_2_15_17_1","unstructured":"T.Volz A.Volmari L.Allweiss et\u00a0al. \u201cPegylated Interferon\u2010Alpha Treatment Potently Reduces All HDV Markers in Primary Human Hepatocytes Undergoing Cell Division In\u00a0Vivo \u201dDelta Cure 3rd International Meeting Poster #19 https:\/\/www.deltacure2024.com\/download\/poster\/P19.pdf."},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314134"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.035"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13356"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae045"},{"key":"e_1_2_15_22_1","unstructured":"S.D'Anna L.Piermatteo G.Brancaccio et\u00a0al. \u201cHDV Persistence Can be Independent From the Extent of HBV Reservoir and Can be Sustained by HBsAg Production Mainly Derived From HBV\u2010DNA Integration \u201dDelta Cure 3rd International Meeting Poster #55 https:\/\/www.deltacure2024.com\/download\/poster\/P55.pdf."},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00649-z"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1821"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13804"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.016"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70003"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.11.051"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13834"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13205"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13235"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17878"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.008"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.005"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022"},{"key":"e_1_2_15_36_1","unstructured":"Food and Drug Administration \u201cChronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry \u201dhttps:\/\/www.fda.gov\/media\/132137\/download."},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.002"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000584"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000975"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3281"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104932"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28772"},{"key":"e_1_2_15_43_1","unstructured":"A.Gerber M.Breuer V.Delagarde et\u00a0al. \u201cHepatitis Delta Virus RNA Quantification: A Story About Fruitful Collaboration Between Private Company and Academic Laboratory \u201dDelta Cure 3rd International Meeting Poster #15 https:\/\/www.deltacure2024.com\/download\/poster\/P15.pdf."},{"key":"e_1_2_15_44_1","unstructured":"L.Piermatteo R.Salpini G. P.Caviglia et\u00a0al. \u201cDiagnostic Performances of Different HDV RNA Quantification Assays Used in Clinical Practice in Italy: Results From a National Quality Control Multicenter Study \u201dDelta Cure 3rd International Meeting Poster #14 https:\/\/www.deltacure2024.com\/download\/poster\/P14.pdf."},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15795"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101299"},{"key":"e_1_2_15_47_1","unstructured":"J. C.Eichholz B.Bremer H.Wedemeyer B.Maasoumy andL.Sandmann \u201cClinical Evaluation of the Altostar HDV RT\u2010PCR Kit 1.5 \u201dDelta Cure 3rd International Meeting Poster #16 https:\/\/www.deltacure2024.com\/download\/poster\/P16.pdf."},{"key":"e_1_2_15_48_1","unstructured":"I.Carey M.Anderson Z.Cargill et\u00a0al. \u201cHDV RNA Assay Sensitivity is Critical for Determining a Correct Outcome During Bulevirtide Antiviral Therapy \u201dDelta Cure 3rd International Meeting Poster #18 https:\/\/www.deltacure2024.com\/download\/poster\/P18.pdf."},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2276337"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)02105-0"},{"key":"e_1_2_15_51_1","unstructured":"V.Delagarde A.Gerber S.Dziri E.Gordien F.Le Gal andS.Brichler \u201cImproving Access to HDV Testing Using Dry Blood Spots \u201dDelta Cure 2nd International Meeting Poster #17."},{"key":"e_1_2_15_52_1","doi-asserted-by":"crossref","unstructured":"A. N.Dashdorj K.An N.Ariungerel et\u00a0al. \u201cValidation of Streamlined Serodiagnosis of Hepatitis Delta Virus \u201dDelta Cure 3rd International Meeting Poster #9 https:\/\/www.deltacure2024.com\/download\/poster\/P9.pdf.","DOI":"10.2139\/ssrn.4987232"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.032"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.015"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13366"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15745"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.038"},{"key":"e_1_2_15_59_1","first-page":"206","article-title":"Polymorphisms in the IL28B Gene (rs12979860, rs8099917) and the Virological Response to Pegylated Interferon Therapy in Hepatitis D Virus Patients","volume":"79","author":"Yilmaz B.","year":"2016","journal-title":"Acta Gastroenterologica Belgica"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.11.006"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14000"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.05.029"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13734"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00318-8"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30651-6"},{"key":"e_1_2_15_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.010"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213429"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.05.001"},{"key":"e_1_2_15_69_1","doi-asserted-by":"crossref","unstructured":"P.Lampertico S.Aleman M.Brunetto et\u00a0al. \u201cEfficacy and Safety of 144\u2009Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301 \u201dDelta Cure 3rd International Meeting Poster #27 https:\/\/www.deltacure2024.com\/download\/poster\/P27.pdf.","DOI":"10.1136\/gutjnl-2024-BASL.137"},{"key":"e_1_2_15_70_1","doi-asserted-by":"crossref","unstructured":"P.Lampertico H.Wedemeyer M. R.Brunetto et\u00a0al. \u201cContinued Treatment of Early Virologic Nonresponders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses: Results From an Integrated Analysis at Week 96 \u201dDelta Cure 3rd International Meeting Poster #26 https:\/\/www.deltacure2024.com\/download\/poster\/P26.pdf.","DOI":"10.1136\/gutjnl-2023-BASL.146"},{"key":"e_1_2_15_71_1","unstructured":"P.Lampertico S.Aleman P.Bogomolov et\u00a0al. \u201cImprovement in Liver Histology Is Observed in Most Patients With Chronic Hepatitis Delta After 48\u2009Weeks of Bulevirtide Monotherapy \u201dDelta Cure 3rd International Meeting Poster #31 https:\/\/www.deltacure2024.com\/download\/poster\/P31.pdf."},{"key":"e_1_2_15_72_1","doi-asserted-by":"crossref","unstructured":"S.Aleman H.Wedemeyer M. R.Brunetto et\u00a0al. \u201cHigh Rates of Adherence to Bulevirtide Monotherapy for Chronic Hepatitis Delta Through 96\u2009Weeks: Results From an Interim Analysis of the Phase 3 Study MYR301 \u201dDelta Cure 3rd International Meeting Poster #40 https:\/\/www.deltacure2024.com\/download\/poster\/P40.pdf.","DOI":"10.1016\/S0016-5085(24)04142-8"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.031"},{"key":"e_1_2_15_74_1","unstructured":"M.Buti H.Wedemeyer S.Aleman et\u00a0al. \u201cPatient\u2010Reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevirtide 2 mg: Analysis of the Phase 3 MYR301 Trial at 96\u2009Weeks \u201dDelta Cure 3rd International Meeting Poster #36 https:\/\/www.deltacure2024.com\/download\/poster\/P36.pdf."},{"key":"e_1_2_15_75_1","doi-asserted-by":"crossref","unstructured":"F.Zoulim V.Chulanov P.Lampertico et\u00a0al. \u201cUndetectable HDV RNA at 24\u2009Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa\u20102a Combination Therapy Is an Important Predictor of Maintained Response Off Therapy \u201dDelta Cure 3rd International Meeting Poster #38 https:\/\/www.deltacure2024.com\/download\/poster\/P38.pdf.","DOI":"10.1016\/S0168-8278(24)02136-6"},{"key":"e_1_2_15_76_1","doi-asserted-by":"crossref","unstructured":"F.Zoulim T.Asselah V.Chulanov et\u00a0al. \u201cUndetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and\/or Pegylated Interferon Alpha\u20102a Is an Important Predictor of 48\u2009Weeks Sustained Virologic Response in Chronic Hepatitis Delta \u201dDelta Cure 3rd International Meeting Poster #39 https:\/\/www.deltacure2024.com\/download\/poster\/P39.pdf.","DOI":"10.1016\/S0168-8278(24)02207-4"},{"key":"e_1_2_15_77_1","unstructured":"D.Roulot F.Zoulim V.Chulanov et\u00a0al. \u201cImprovements in Fibrosis and Necroinflammation With Bulevirtide Combined With Pegylated Interferon for Chronic Hepatitis Delta \u201dDelta Cure 3rd International Meeting Poster #41 https:\/\/www.deltacure2024.com\/download\/poster\/P41.pdf."},{"key":"e_1_2_15_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.044"},{"key":"e_1_2_15_79_1","unstructured":"M. P.Anolli E.Degasperi G.D'Offizi et\u00a0al. \u201cBulevirtide for Patients With Chronic Hepatitis D (CHD) in Italy: A Multicenter Prospective Nationwide Real\u2010Life Study (D\u2010SHIELD) \u201dDelta Cure 3rd International Meeting Poster #23 https:\/\/www.deltacure2024.com\/download\/poster\/P23.pdf."},{"key":"e_1_2_15_80_1","unstructured":"E.Degasperi A.De Silvestri andM. P.Anolli \u201cBulevirtide Monotherapy Prevents Liver Decompensation in Patients With HDV\u2010Related Cirrhosis: A Case Control Study With Propensity Score Weighted Analysis \u201dDelta Cure 3rd International Meeting Poster #25 https:\/\/www.deltacure2024.com\/download\/poster\/P25.pdf."},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101057"},{"key":"e_1_2_15_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000847"},{"key":"e_1_2_15_83_1","unstructured":"S.Aleman P.Lampertico M. R.Brunetto et\u00a0al. \u201cEfficacy and Safety of BLV Monotherapy for Chronic Hepatitis Delta: Posttreatment Results Through 24\u2009Weeks After the End of Treatment From an Interim Analysis of a Randomised Phase 3 Study MYR301 \u201dDelta Cure 3rd International Oral Communication."},{"key":"e_1_2_15_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(24)02220-7"},{"key":"e_1_2_15_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101070"},{"key":"e_1_2_15_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100966"},{"key":"e_1_2_15_87_1","unstructured":"O.Wasserman L.Shekhtman S. J.Cotler et\u00a0al. \u201cBulevirtide Monotherapy in Patients With Compensated Cirrhosis and CSPH: A 96\u2010Week Interim Kinetic Analysis \u201dDelta Cure 3rd International Meeting Poster #30 https:\/\/www.deltacure2024.com\/download\/poster\/P30.pdf."},{"key":"e_1_2_15_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000309"},{"key":"e_1_2_15_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)00451-8"},{"key":"e_1_2_15_90_1","doi-asserted-by":"crossref","unstructured":"T.Asselah A.Streinu\u2010Cercel A.Jucov et\u00a0al. \u201cEfficacy and Safety of Tobevibart (VIR\u20103434) Alone or in Combination With Elebsiran (VIR\u20102218) in Participants With Chronic Hepatitis Delta Virus Infection: Preliminary Results From the Phase 2 SOLSTICE Trial in Non\u2010Cirrhotic and Compensated Cirrhotic Participants \u201dDelta Cure International 3rd Meeting Oral Communication https:\/\/www.deltacure2024.com\/download\/poster\/P32.pdf.","DOI":"10.1016\/S0168-8278(24)00565-8"},{"key":"e_1_2_15_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(24)00569-5"},{"key":"e_1_2_15_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(24)00475-6"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.70189","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:36:07Z","timestamp":1772958967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/liv.70189"],"URL":"https:\/\/doi.org\/10.1111\/liv.70189","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2025-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70189"}}